IC
Ikarian Capital Portfolio holdings
AUM
$699M
1-Year Est. Return
600.17%
This Fund
S&P 500
1 Year Est. Return
+600.17%
AUM
$773M
AUM Growth
+$278M
(+56%)
Holding
181
Top Buys
| 1 | +$33.1M | |
| 2 | +$14.6M | |
| 3 | +$14.3M | |
| 4 |
Olema Pharmaceuticals
OLMA
|
+$13.5M |
| 5 |
Eli Lilly
LLY
|
+$13.2M |
Top Sells
| 1 | +$53M | |
| 2 | +$20.7M | |
| 3 | +$16M | |
| 4 |
Dianthus Therapeutics
DNTH
|
+$13.6M |
| 5 |
PTC Therapeutics
PTCT
|
+$11.8M |
Sector Composition
| 1 | Healthcare | 99.47% |
| 2 | Financials | 0.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
176
Dianthus Therapeutics
DNTH
$4.59B
| – | – |
-346,001
|
|
||
177
DexCom
DXCM
$28.1B
| – | – |
0
|
|
||
178
Dyne Therapeutics
DYN
$2.92B
| – | – |
-113,837
|
|
||
179
Genmab
GMAB
$14.6B
| – | – |
-175,000
|
|
||
180
Gossamer Bio
GOSS
$44.3M
| – | – |
0
|
|
||
181
InflaRx
IFRX
$303M
| – | – |
-722,066
|
|